Regulation of autologous immunity to the mouse 5T4 oncofoetal antigen: implications for immunotherapy.
Authors
Castro, Fernanda VAl-Muftah, Mariam
Mulryan, Kate
Jiang, Hui-Rong
Drijfhout, Jan W
Ali, Sumia
Rutkowski, Andrzej J
Kalaitsidou, Milena
Gilham, David E
Stern, Peter L
Affiliation
Immunology Group, Paterson Institute for Cancer Research, University of Manchester, Wilmslow Road, Withington, Manchester, M20 4BX, UK.Issue Date
2011-11-30
Metadata
Show full item recordAbstract
Effective vaccination against tumour-associated antigens (TAA) such as the 5T4 oncofoetal glycoprotein may be limited by the nature of the T cell repertoire and the influence of immunomodulatory factors in particular T regulatory cells (Treg). Here, we identified mouse 5T4-specific T cell epitopes using a 5T4 knock out (5T4KO) mouse and evaluated corresponding wild-type (WT) responses as a model to refine and improve immunogenicity. We have shown that 5T4KO mice vaccinated by replication defective adenovirus encoding mouse 5T4 (Adm5T4) generate potent 5T4-specific IFN-γ CD8 and CD4 T cell responses which mediate significant protection against 5T4 positive tumour challenge. 5T4KO CD8 but not CD4 primed T cells also produced IL-17. By contrast, Adm5T4-immunized WT mice showed no tumour protection consistent with only low avidity CD8 IFN-γ, no IL-17 T cell responses and no detectable CD4 T cell effectors producing IFN-γ or IL-17. Treatment with anti-folate receptor 4 (FR4) antibody significantly reduced the frequency of Tregs in WT mice and enhanced 5T4-specific IFN-γ but reduced IL-10 T cell responses but did not reveal IL-17-producing effectors. This altered balance of effectors by treatment with FR4 antibody after Adm5T4 vaccination provided modest protection against autologous B16m5T4 melanoma challenge. The efficacy of 5T4 and some other TAA vaccines may be limited by the combination of TAA-specific T regs, the deletion and/or alternative differentiation of CD4 T cells as well as the absence of distinct subsets of CD8 T cells.Citation
Regulation of autologous immunity to the mouse 5T4 oncofoetal antigen: implications for immunotherapy. 2011: Cancer Immunol ImmunotherJournal
Cancer Immunology ImmunotherapyDOI
10.1007/s00262-011-1167-3PubMed ID
22127365Type
ArticleLanguage
enISSN
1432-0851ae974a485f413a2113503eed53cd6c53
10.1007/s00262-011-1167-3
Scopus Count
Collections
Related articles
- 5T4 oncofoetal glycoprotein: an old target for a novel prostate cancer immunotherapy.
- Authors: Cappuccini F, Pollock E, Stribbling S, Hill AVS, Redchenko I
- Issue date: 2017 Jul 18
- Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma.
- Authors: Saenger YM, Li Y, Chiou KC, Chan B, Rizzuto G, Terzulli SL, Merghoub T, Houghton AN, Wolchok JD
- Issue date: 2008 Dec 1
- The nature of the human T cell response to the cancer antigen 5T4 is determined by the balance of regulatory and inflammatory T cells of the same antigen-specificity: implications for vaccine design.
- Authors: Besneux M, Greenshields-Watson A, Scurr MJ, MacLachlan BJ, Christian A, Davies MM, Hargest R, Phillips S, Godkin A, Gallimore A
- Issue date: 2019 Feb
- Immunotherapy success in prophylaxis cannot predict therapy: prime-boost vaccination against the 5T4 oncofoetal antigen.
- Authors: Ali S, Mulryan K, Taher T, Stern PL
- Issue date: 2007 Feb
- Murine responses to recombinant MVA versus ALVAC vaccines against tumor-associated antigens, gp100 and 5T4.
- Authors: Hanwell DG, McNeil B, Visan L, Rodrigues L, Dunn P, Shewen PE, Macallum GE, Turner PV, Vogel TU
- Issue date: 2013 May